EDURANT 25 mg film-coated tablets
Sponsors
Fundacion Seimc Gesida, Fundacion Seimc Gesida, Fundacion Fls De Lucha Contra El Sida Las Enfermedades Infecciosas Y La Promocion De La Salud Y La C, Fundacion Fls De Lucha Contra El Sida Las Enfermedades Infecciosas Y La Promocion De La Salud Y La C, Stichting Radboud universitair medisch centrum
Conditions
HIV-Infected patientsHIV-infectedMetabolic liver disease in HIV-infected people
Phase 4
Phase IV comparative, randomized, open-label pilot study to evaluate the efficacy and safety of a rilpivirine-based antiretroviral treatment regimen in HIV-infected patients with metabolic liver disease who maintain undetectable HIV viral load
CompletedCTIS2022-503110-23-00
Start: 2023-05-05End: 2025-07-07Target: 75Updated: 2023-08-28
Implementation of Out-of-HOspital administration of the Long-Acting combination cabotegravir+rilpivirine as an optional therapy in HIV-Infected patients from Spain. Acceptability, appropriateness, feasibility and satisfaction. The HOLA Study.
CompletedCTIS2023-503963-41-00
Start: 2023-10-05End: 2025-05-30Target: 110Updated: 2024-06-07
Study on Pharmacokinetics of newly developed ANtiretroviral agents in HIV-infected pregNAnt women (PANNA)
CompletedCTIS2024-515487-31-00
End: 2025-12-12Target: 163Updated: 2024-10-22